DK2004683T3 - Pc5 som et faktor ix-propeptid-forarbejdende enzym - Google Patents

Pc5 som et faktor ix-propeptid-forarbejdende enzym Download PDF

Info

Publication number
DK2004683T3
DK2004683T3 DK07753848.6T DK07753848T DK2004683T3 DK 2004683 T3 DK2004683 T3 DK 2004683T3 DK 07753848 T DK07753848 T DK 07753848T DK 2004683 T3 DK2004683 T3 DK 2004683T3
Authority
DK
Denmark
Prior art keywords
profix
fix
fusion protein
gly
ser
Prior art date
Application number
DK07753848.6T
Other languages
English (en)
Inventor
Robert T Peters
Alan Bitonti
Original Assignee
Biogen Hemophilia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Hemophilia Inc filed Critical Biogen Hemophilia Inc
Application granted granted Critical
Publication of DK2004683T3 publication Critical patent/DK2004683T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (22)

1. Eukaryot celle omfattende et første polynukleotid, der koder for et proprotein af Faktor IX (proFIX), eller et fusionsprotein deraf, og et andet polynukleotid, der koder for en funktionel pattedyr-subtilisin/Kex2p-lignende proproteinkonvertase PC5.
2. Eukaryot celle ifølge krav 1, hvor den funktionelle PC5 omfatter en aminosyresekvens fra SEQ ID NO: 1.
3. Eukaryot celle ifølge krav 1, hvor det første polynukleotid koder for proFIX.
4. Eukaryot celle ifølge krav 1, hvor det første polynukleotid koder for et fusionsprotein af proFIX.
5. Eukaryot celle ifølge krav 4, hvor fusionsproteinet er et proFIX-FcRn- bindingspartnerfusionsprotein.
6. Eukaryot celle ifølge krav 5, hvor proFIX-FcRn-bindingspartnerfusionsproteinet er et proFIX-Fc-fusionsprotein.
7. Eukaryot celle ifølge krav 6, hvor proFIX-Fc-fusionsproteinet omfatter et human Fc- gamma.
8. Eukaryot celle ifølge krav 6, hvor cellen producerer en proFIX-Fc-homodimer.
9. Eukaryot celle ifølge krav 6, hvor cellen producerer en proFIX-Fc-monomer-dimer hybrid.
10. Eukaryot celle ifølge krav 4, hvor fusionsproteinet er et proFIX-albumin- fusionsprotein.
11. Eukaryot celle ifølge krav 4, hvor fusionsproteinet er et proFIX-transferrin-fusionsprotein.
12. Eukaryot celle ifølge krav 4, hvor fusionsproteinet omfatter en linker.
13. Eukaryot celle ifølge krav 12, hvor linkereb er GGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 16).
14. Eukaryot celle ifølge krav 1, hvor den eukaryote celle er en pattedyrecelle.
15. Eukaryot celle ifølge krav 1, hvor den eukaryote celle er en HEK 293-celle.
16. Eukaryot celle ifølge krav 1, hvor den eukaryote celle er en CHO-celle.
17. Eukaryot celle ifølge krav 1, hvor det første polynukleotid, der koder for proFIX eller fusionsproteinet deraf, og det andet polynukleotid, der koder for den funktionelle PC5, er i en enkelt ekspressionsvektor.
18. Ekspressionsvektor omfattende en første polynukleotidsekvens, der koder for et proprotein af Faktor IX (proFIX), eller et fusionsprotein deraf, der er operativt bundet til en ekspressionskontrolsekvens, der tillader ekspression af proFIX eller fusionsproteinet deraf, og en anden polynukleotidsekvens, der koder for en funktionel pattedyr-subtilisin/Kex2p-lignende proproteinkonvertase PC5, der er operativt bundet til en ekspressionskontrolsekvens, der tillader ekspression af den funktionelle PC5.
19. Fremgangsmåde til fremstilling af et maturt Faktor IX-holdigt polypeptid ud af et proprotein af Faktor IX (proFIX), eller et fusionsprotein deraf, hvilken fremgangsmåde omfatter dyrkning af eukaryot celle ifølge krav 1 under forhold, der tillader: ekspression af både proFIX eller fusionsproteinet deraf og den funktionelle PC5 og forarbejdning af proFIX eller fusionsproteinet deraf ved den funktionelle PC5.
20. Fremgangsmåde til at øge udbyttet af et maturt Faktor IX-holdigt polypeptid fra et proprotein af Faktor IX (proFIX), eller et fusionsprotein deraf, hvilken fremgangsmåde omfatter dyrkning af den eukaryote celle ifølge krav 1 under forhold, der tillader: ekspression af både proFIX eller fusionsproteinet deraf og den funktionelle PC5, og forarbejdning af proFIX eller fusionsproteinet deraf ved den funktionelle PC5, hvor udbyttet af maturt Faktor IX-holdigt polypeptid er øget sammenlignet med udbyttet af maturt Faktor IX-holdigt polypeptid, der er fremstillet under tilsvarende forhold uden forarbejdning ved den funktionelle PC5.
21. Fremgangsmåde in vitro til fremstilling af et maturt Faktor IX-holdigt polypeptid ud fra et proprotein af Faktor IX (proFIX), et fusionsprotein deraf eller et konjugat deraf, hvilken fremgangsmåde omfatter etablering af kontakt mellem proFIX eller konjugatet deraf med en effektiv mængde af en funktionel pattedyr-subtilisin/Kex2p-lignende proproteinkonvertase PC5.
22. Fremgangsmåde ifølge 21, hvor proFIX eller konjugatet deraf er et PEGyleret proFIX.
DK07753848.6T 2006-03-24 2007-03-23 Pc5 som et faktor ix-propeptid-forarbejdende enzym DK2004683T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78542106P 2006-03-24 2006-03-24
PCT/US2007/007252 WO2007112005A2 (en) 2006-03-24 2007-03-23 Pc5 as a factor ix propeptide processing enzyme

Publications (1)

Publication Number Publication Date
DK2004683T3 true DK2004683T3 (da) 2016-08-22

Family

ID=38541681

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07753848.6T DK2004683T3 (da) 2006-03-24 2007-03-23 Pc5 som et faktor ix-propeptid-forarbejdende enzym

Country Status (11)

Country Link
US (3) US7566565B2 (da)
EP (2) EP2650305B1 (da)
DK (1) DK2004683T3 (da)
HK (1) HK1125656A1 (da)
HR (1) HRP20160990T1 (da)
HU (1) HUE030567T2 (da)
LT (1) LT2004683T (da)
PL (1) PL2650305T3 (da)
SI (1) SI2004683T1 (da)
TW (1) TWI428448B (da)
WO (1) WO2007112005A2 (da)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2006068760A2 (en) 2004-11-19 2006-06-29 The Regents Of The University Of California Anti-inflammatory pyrazolopyrimidines
EP2650305B1 (en) * 2006-03-24 2024-05-08 Bioverativ Therapeutics Inc. PC5 as a factor IX propeptide processing enzyme
PT2004654E (pt) 2006-04-04 2013-08-27 Univ California Derivados de pirazolopirimidina para utilização como antagonistas da quinase
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
ES2647163T3 (es) 2008-01-04 2017-12-19 Intellikine, Inc. Derivados de isoquinolinona sustituidos con una purina útiles como inhibidores de la PI3K
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
EP2252293B1 (en) 2008-03-14 2018-06-27 Intellikine, LLC Kinase inhibitors and methods of use
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
KR20110039326A (ko) 2008-07-08 2011-04-15 인텔리카인, 인크. 키나제 억제제 및 사용 방법
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
JP5819195B2 (ja) 2008-10-16 2015-11-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 融合環ヘテロアリールキナーゼ阻害剤
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
JP5764145B2 (ja) 2010-02-08 2015-08-12 メルク・シャープ・エンド・ドーム・ベー・フェー ８−メチル−１−フェニル−イミダゾル［１，５−ａ］ピラジン化合物
AU2011255218B2 (en) 2010-05-21 2015-03-12 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2576625B1 (en) * 2010-06-04 2018-04-25 TiumBio Co., Ltd. Fusion protein having factor vii activity
US10513563B2 (en) 2010-07-02 2019-12-24 University Of Southern California Method for uses of proinsulin transferrin fusion proteins as prodrugs
WO2012003398A1 (en) * 2010-07-02 2012-01-05 University Of Southern California Method for uses of protein precursors as prodrugs
EP3508573A1 (en) * 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
PT2591006T (pt) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
CN103140237A (zh) * 2010-07-09 2013-06-05 比奥根艾迪克依蒙菲利亚公司 因子ix多肽及其使用方法
KR101853405B1 (ko) * 2010-10-20 2018-05-02 주식회사 티움바이오 인자 ｉｘ 활성을 갖는 융합 단백질
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
EP2637669A4 (en) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Heterocyclic compounds and their use
CA2824197C (en) 2011-01-10 2020-02-25 Michael Martin Processes for preparing isoquinolinones and solid forms of isoquinolinones
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
JP6027611B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
JP6342805B2 (ja) 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
US9550819B2 (en) 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10202595B2 (en) 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
EP3693000B1 (en) 2012-06-08 2022-03-02 Bioverativ Therapeutics Inc. Procoagulant compounds
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP3542861A1 (en) * 2012-09-25 2019-09-25 Bioverativ Therapeutics Inc. Methods of using fix polypeptides
MX2015003874A (es) 2012-09-26 2015-12-16 Univ California Modulacion de ire1.
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
EP2950807B1 (en) 2013-01-30 2018-03-28 NGM Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
TWI745671B (zh) 2013-03-15 2021-11-11 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CA2907726A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc1/2 inhibitors and selective inhibitors of aurora a kinase
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2943075C (en) 2014-03-19 2023-02-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015148444A1 (en) 2014-03-24 2015-10-01 Biogen Ma Inc. Lyophilized factor ix formulations
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
TN2016000578A1 (en) 2014-07-30 2018-04-04 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
MD20170035A2 (ro) 2014-10-31 2017-09-30 Ngm Biopharmaceuticals Inc Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
NZ740616A (en) 2015-09-14 2023-05-26 Infinity Pharmaceuticals Inc Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
CN109715206B (zh) 2016-03-31 2023-11-07 恩格姆生物制药公司 结合蛋白及其使用方法
US11753438B2 (en) 2016-05-11 2023-09-12 Cytiva Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
EP3455240A1 (en) 2016-05-11 2019-03-20 GE Healthcare BioProcess R&D AB Method of storing a separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
CN109071613A (zh) 2016-05-11 2018-12-21 通用电气医疗集团生物工艺研发股份公司 分离基质
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2018016227A (es) 2016-06-24 2019-07-08 Infinity Pharmaceuticals Inc Terapias de combinacion.
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
EP0246709A1 (en) 1986-05-20 1987-11-25 Stichting Katholieke Universiteit Recombinant DNA and cDNA, mRNA, protein, antibodies, and a method of detecting tumor cells
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5935815A (en) * 1989-10-25 1999-08-10 Katholieke Universiteit Leuven Process for micro biological production of proteins
ATE174058T1 (de) 1989-11-06 1998-12-15 Cell Genesys Inc Herstellung von proteinen mittels homologer rekombination
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
JP4236698B2 (ja) * 1990-11-26 2009-03-11 ジェネティックス インスティチュート，リミテッド ライアビリティ カンパニー 宿主細胞でのｐａｃｅの発現およびその使用法
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
SG47099A1 (en) 1991-03-15 1998-03-20 Amgen Boulder Inc Pegylation of polypeptides
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
DK0654085T3 (da) 1992-01-23 1997-09-22 Merck Patent Gmbh Monomere og dimere antistof-fragment-fusionsproteiner
US5866351A (en) * 1993-07-07 1999-02-02 University Technology Corporation CD4+ T-lymphocyte proteases and genes encoding said proteases
US5691183A (en) * 1993-07-07 1997-11-25 University Technology Corporation CD4+ T-lymphoctye proteases and genes encoding said proteases
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
US5840529A (en) 1995-08-02 1998-11-24 Clinical Research Institute Of Montreal Mammalian pro-hormone convertase
CA2203745A1 (en) 1996-07-26 1998-01-26 Robert Day Pro-protein converting enzyme
JP2005526769A (ja) 2002-03-15 2005-09-08 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 治療剤を全身搬送するための中央気道投与
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ES2558102T3 (es) * 2003-05-06 2016-02-02 Biogen Hemophilia Inc. Proteínas quiméricas del factor de coagulación para el tratamiento de un trastorno hemostático
EP2650305B1 (en) 2006-03-24 2024-05-08 Bioverativ Therapeutics Inc. PC5 as a factor IX propeptide processing enzyme

Also Published As

Publication number Publication date
HK1125656A1 (zh) 2009-08-14
US7566565B2 (en) 2009-07-28
SI2004683T1 (sl) 2016-09-30
WO2007112005A3 (en) 2008-02-07
PL2650305T3 (pl) 2024-09-16
EP2650305A1 (en) 2013-10-16
EP2650305C0 (en) 2024-05-08
TW200815599A (en) 2008-04-01
US20070259402A1 (en) 2007-11-08
US20100015659A1 (en) 2010-01-21
EP2004683A2 (en) 2008-12-24
LT2004683T (lt) 2016-10-10
US20110053222A1 (en) 2011-03-03
WO2007112005A2 (en) 2007-10-04
HUE030567T2 (en) 2017-05-29
EP2650305B1 (en) 2024-05-08
EP2004683B1 (en) 2016-05-11
US8021880B2 (en) 2011-09-20
HRP20160990T1 (hr) 2016-10-07
US7795400B2 (en) 2010-09-14
TWI428448B (zh) 2014-03-01

Similar Documents

Publication Publication Date Title
DK2004683T3 (da) Pc5 som et faktor ix-propeptid-forarbejdende enzym
US20210355473A1 (en) Chimeric clotting factors
JP6441432B2 (ja) 免疫グロブリンキメラ単量体−二量体ハイブリッド
AU2016244273B2 (en) Immunoglobulin Chimeric Monomer-Dimer Hybrids
NO20210848A1 (no) Immunoglobulin kimeriske monomere-dimere hybrider